Previous 10 | Next 10 |
2023-12-11 13:57:54 ET More on MorphoSys MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis MorphoSys: Buying Constellation Was A Desperate Measure MorphoSys: Still Positive Moving Into Pelabresib Data (Maintaining Buy Rating) Mo...
2023-12-11 12:51:49 ET Gainers: Jet.AI ( JTAI ) +70% . Boqii Holding Limited ( BQ ) +34% . Marker Therapeutics ( MRKR ) +34% . Morphosys AG ( MOR ) +25% . G1 Therapeutics ( GTHX ) +24% . Innoviz Technologies Ltd ( INVZ ) ...
2023-12-11 10:00:03 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Veru, Kodiak S...
Pelabresib and ruxolitinib combination significantly reduced spleen size, with an SVR35 response rate nearly double that of placebo plus ruxolitinib Showed a strong positive trend in reducing symptom burden and a twofold increase in patients achieving both SVR35 and TSS50 versus placebo p...
2023-12-04 13:50:57 ET Summary Geron Corporation has submitted its New Drug Application (NDA) to the FDA for its lead candidate, imetelstat, for the treatment of transfusion-dependent anemia in adult patients with myelodysplastic syndromes. The FDA has accepted Geron's NDA and wil...
2023-12-01 08:25:56 ET Losers: Smart for Life ( SMFL ) -38% announces exercise of warrants for $1.5 Million gross proceeds . Ampio Pharmaceuticals ( AMPE ) -34% . Incannex Healthcare ( IXHL ) -34% . Vivos Therapeutics ( VVOS ) -14% . ...
2023-11-30 17:13:46 ET Gainers: Altimmune ( ALT ) +64% . Domo ( DOMO ) +11% . Ulta Beauty ( ULTA ) +9% . Carisma Therapeutics ( CARM ) +5% . Brookfield Property Partners ( BPYPM ) +4% . Losers: Super Micro Computer ( SM...
2023-11-30 12:24:56 ET DENVER, Colo., Nov. 30, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; VinFast Auto Ltd (NASDAQ: VFS), Minim Inc (NASDAQ: MINM), Smart for Life Inc (NASDAQ: SMFL), Ampio Pha...
2023-11-27 14:00:44 ET Summary MorphoSys announced positive topline results from its phase 3 trial of pelabresib in frontline myelofibrosis, nearly doubling spleen volume reduction (the primary endpoint) compared to placebo. However, key secondary endpoints assessing symptomatic i...
2023-11-22 10:00:14 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...
News, Short Squeeze, Breakout and More Instantly...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (“ADSs”) from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Ex...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...